CD151 is a member of the mammalian tetraspanins, which are transmembrane proteins involved in a variety of biological processes including the immune system, fertilisation, infectious processes, and tumour progression ([@bib13]; [@bib8]). Tetraspanin proteins form complexes between themselves or with other non-tetraspanin molecules such as integrins, immunoglobulin superfamily members, and signalling molecules, and carry out several functions depending on interacting partners ([@bib7]; [@bib32]). Particularly, CD151 contributes to integrin-dependent cell adhesion and motility by directly interacting with laminin-binding integrins (*α*~3~*β*~1~, *α*~6~*β*~1~, *α*~6~*β*~4~, and *α*~7~*β*~1~) ([@bib8]). A recent study also reported that CD151 has a role in proliferation of mammalian epithelial cells, suggesting that CD151 may contribute to the tumour cell growth ([@bib15]). Tetraspanin CD151 is expressed in most of cells and tissue types showing high expression in epithelial and endothelial cells ([@bib20]; [@bib32]). Deregulation of several tetraspanins is observed in human cancer, and these upregulation or downregulation are of clinical significance in some malignancies ([@bib16]). Upregulation of CD151 is found in many tumour types and CD151 overexpression was associated with poor prognosis in non-small cell lung ([@bib23]), colon cancer ([@bib6]), hepatocellular ([@bib11]), pancreatic ([@bib30]), oesophageal ([@bib21]), and endometrial cancer ([@bib24]). In addition, there have been several evidences supporting the contribution of CD151 in tumour progression. Although tetraspanins CD82 and CD9 are known to suppress metastasis ([@bib32]), CD151 promotes metastasis by regulating tumour cell migration ([@bib31]). Specifically, overexpression of CD151 enhances cell motility, invasion, and metastasis in colon cancer and fibrosarcoma cells ([@bib12]). In hepatocelluar carcinoma cells, CD151 expression promotes invasiveness of tumour cells in association with induction of epithelial--mesenchymal transitions ([@bib10]).

Based on the association of *α*~6~*β*~4~ integrin in mammary tumourigenesis ([@bib19]; [@bib29]; [@bib5]), the relevance of CD151 in breast cancer was also hypothesised. Indeed, [@bib27] showed that CD151 expression is elevated in breast cancer, with even more upregulation in high-grade and oestrogen-negative subtypes including basal-like breast cancer. Moreover, it was demonstrated that loss of CD151 decreased the integrin-mediated cell migration, spreading, invasion, and signalling (through FAK, Rac1, and lck) of basal-like mammary cell lines with the effect on the subcellular distribution of *α*~6~ integrins ([@bib27]). The delayed breast cancer progression by CD151 ablation was also shown in mouse xenograft models established using basal-like cell line, suggesting that CD151 may be a novel therapeutic target in certain breast cancer subtypes ([@bib27]). High expression of CD151 in high-grade breast cancer was also confirmed in the recent study by [@bib17]). Furthermore, in the same study, CD151 overexpression was shown to correlate with decreased survival of patients with breast cancer when assessed in 56 cases ([@bib17]). However, the association of CD151 expression with clinical outcome as well as its significance as prognostic factor in breast cancer patients is still unclear. Moreover, a systematic approach examining the incidence of CD151 expression and the significance of CD151 on clinical outcomes in breast cancer subtypes has not been undertaken. In order to select the appropriate breast cancer patients for targeted therapy, a detailed analysis using marker-driven subtyping in patient populations is critical. Therefore, to define the prognostic impact of CD151 expression in breast cancer subtypes, we divided 886 patients with breast cancer into five subtypes and assessed the relationship of CD151 expression with clinical outcome including overall survival (OS) and disease-free progression survival in each subtype.

Materials and Methods
=====================

Study samples and five subtypes information
-------------------------------------------

A tissue microarray (TMA) constructed from duplicate 2 mm cores of invasive breast carcinomas from 1290 primary invasive breast cancer samples was utilised for the analysis of CD151 status. This retrospective cohort was named 'Samsung Medical Center Breast Cancer Biomarker Study\' and was originally intended for the clinical validation of a novel biomarker set according to the breast cancer subtype ([@bib4]). The clinical features of this cohort were as follows: (1) patients did not receive cytotoxic chemotherapy or hormones before surgery; (2) all oestrogen receptor (ER)-positive patients underwent hormonal therapy with tamoxifen; (3) none of the patients underwent anti-human epidermal growth factor receptor 2 (HER2) therapy. The pathological tumour stage was assessed according to the American Joint Committee on Cancer (AJCC) 6 Staging System. The histological grade was determined according to the Bloom--Richardson classification scheme. This study was approved by the Institutional Review Board at the Samsung Medical Center (Seoul, Korea) in accordance with the Declaration of Helsinki.

Only 951 of the cases had subtype information ([@bib4]). Each case was divided into five subgroups according to the status of ER, progesterone receptor (PR), HER2, and basal markers (either epidermal growth factor receptor (EGFR) or cytokeratin 5/6 (CK5/6)) as described previously ([@bib4]): (1) Luminal A (ER+ or PR+/HER2−), (2) Luminal B (ER+ or PR+/HER2+), (3) HER2 (ER−/PR−/HER2+), triple-negative breast cancer (TNBC, ER−/PR−/HER2−), TNBC subtype was further divided into (4) basal-like breast cancer (BLBC, ER−/PR−/HER2−/EGFR+ or CK5/6+), and (5) quintuple-negative breast cancer (QNBC, ER−/PR−/HER2−/EGFR−/CK5/6−) ([@bib4]). Although the ER and PR status were acquired from the pathological report using the semi-quantitative Allred score, the HER2, CK5/6, and EGFR status were determined from the TMA analysis. Tumours were classified as HER2 positive if they had a score of 3+ in regard to the staining on IHC and/or gene amplification as determined by fluorescence *in situ* hybridisation when using HER2, such that the chromosome 17 ratio was \>2.2. Cytokeratin 5/6 was interpreted as positive if there was any observation of cytoplasm and/or membranous staining. The EGFR status was scored as positive when at least 10% of the tumour cells showed strong membranous staining.

Immunohistochemical analysis
----------------------------

Immunohistochemical analyses were performed on the paraffin sections as described previously ([@bib3]). The TMA sections were incubated with the monoclonal mouse anti-human CD151 antibody at room temperature for 60 min (1 : 100 dilution, RLM30, Novocastra, Newcastle upon Tyne, UK). Specimens were then incubated with a 1 : 1000 dilution of biotinylated goat anti-mouse IgG (Vector Laboratories, Burlingame, CA, USA) for 1 h at room temperature after washing with PBS. CD151 expression was scored using the HER2 semi-quantitative method based on the following four classes ([@bib25]): score 0 (no staining is observed or cell membrane staining is observed in \<10% of the tumour cells), score 1+ (a faint perceptible membrane staining can be detected in \>10% of the tumour cells. The cells are only stained in parts of their membrane), score 2+ (a weak to moderate complete membrane staining is observed in \>10% of the tumour cells), and score 3+ (a strong complete membrane staining is observed in \>30% of the tumour cells). Scores ranging from 0 to 2+ were classified as CD151-low expression and cases that had a score of 3+ were classified into the CD151-high expression group. Two pathologists (MJK and YLC) independently scored the immunohistochemical staining and were blinded with respect to the results of the other markers and the outcome data.

Statistical analysis
--------------------

Disease-free survival (DFS) was defined as the time from the date of diagnosis to the date of documented relapse, including locoregional recurrence and distant metastasis. Overall survival was expressed as the number of months from diagnosis of breast cancer to the date of death. Differences in the frequencies of the basic characteristics, clinical parameters, and subtypes were statistically analysed using either the chi-square test or the Fisher\'s exact test in cases when the expected values of any of the cells were \<5. Survival curves were constructed using the Kaplan--Meier method and the log-rank test was used to compare the mean survival rates across the groups. The log-rank test with Bonferroni\'s correction was used for the subgroup survival analysis. For the multivariate analysis, Cox regression models were constructed in order to estimate the adjusted hazard ratios (HRs) of the groups according to stage, adjuvant chemotherapy, and subtype. *P*-values \<0.05 were considered to be statistically significant and all of the *P*-values corresponded to two-sided significance tests. All of the statistical analyses were performed using SPSS 16.0 (Chicago, IL, USA). The 'REMARK\' criteria of the National Cancer Institute was used in the design, analysis, and interpretation of the results ([@bib14]).

Results
=======

Patient characteristics and CD151 expression
--------------------------------------------

In 65 cases, CD151 stain was considered to be unsatisfactory because of loss of tissue core or no invasive cancer component, and these cases were further excluded from 951 cases with subtype information. Therefore, a total of 886 cases with informative immunohistochemical results were included in this analysis. All of the patients were Korean females who had curative resection of their primary tumours and axillary node dissection or sentinel node sampling. The median age at diagnosis was 46 years (range, 23--80 years). The characteristics of the patients are provided in [Table 1](#tbl1){ref-type="table"}. In the normal breast tissue, CD151 was expressed in the basal-myoepithelial cell layer surrounding both ducts and tubule-lobular units ([Figures 1A and B](#fig1){ref-type="fig"}). The invasive cancers showed CD151 expression predominantly localised to the membrane, with expression occurring in the cytoplasm in some cases ([Figures 1D, E and F](#fig1){ref-type="fig"}). The numbers of patients in each group of CD151 expression were as follows: score 0, 80 (9.0%); score 1, 356 (40.2%); score 2, 323 (36.5%); and score 3, 127 (14.3%). In all, 127 (14.3%) cases were identified as CD151-high expression and 759 (85.7%) cases were classified as CD151-low expression. CD151 overexpression was significantly associated with a more advanced stage (*P*\<0.001), larger tumour size (*P*\<0.001), lymph node involvement (*P*\<0.001), and absence of ER (*P*\<0.001) and PR (*P*=0.009) ([Table 1](#tbl1){ref-type="table"}). There were no significant differences in the distribution of adjuvant chemotherapy modalities between the CD151-low group and the CD151-high group (*P*=0.409). CD151 overexpression was detected more frequently in breast cancers with HER2 overexpression (21.9%) than in HER2-negative breast cancers (11.8%, *P*\<0.001). When CD151 overexpression was compared among the breast cancer subtypes (Luminal A, Luminal B, HER2, BLBC, and QNBC), CD151 overexpression varied significantly according to the breast cancer subtype (*P*\<0.001). The Luminal A subtype had a lower incidence in tumours with CD151 expression. CD151 overexpression was most frequent in the HER2 subtype (27.4%) ([Table 1](#tbl1){ref-type="table"}).

Impact of CD151 overexpression on survival in breast cancer according to stage and subtype
------------------------------------------------------------------------------------------

The time of DFS ranged from 0 to 148.7 months with a median of 68.8 months. During the study period, 24.6% of the women (218 out of 886) had local recurrence and/or metastasis. Duration of OS ranged from 6.0 to 148.7 months with a median of 74.9 months. During the study period, 14.1% of women (125 out of 886) died, whereas the remaining 761 were still alive at the end of the study. The breast cancer patients with CD151 overexpression demonstrated substantially poorer OS (CD151-high *vs* CD151-low; 109.8 months (95% confidence interval (CI), 100.9--118.7 months) *vs* 134.1 months (95% CI, 131.3--137.0 months), *P*\<0.001) and DFS (CD151-high *vs* CD151-low; 104.2 months (95% CI, 94.6--113.7 months) *vs* 120.0 months (95% CI, 116.2--123.7 months), *P*=0.020) ([Figure 2A](#fig2){ref-type="fig"}). We performed survival analyses according to the AJCC stage of the breast cancer. Although CD151 overexpression did not show any impact on survival in regard to AJCC stage I cancer, CD151 overexpression had a significant influence on OS in stage II cancer (CD151-high *vs* CD151-low, 117.3 months (95% CI, 106.2--128.4 months) *vs* 135.6 months (95% CI, 131.7--139.5 months), *P*=0.0474) and stage III cancer (CD151-high *vs* CD1515-low, 86.7 months (95% CI, 70.9--102.5 months) *vs* 110.4 months (103.1--117.7 months), *P*=0.0169) ([Figure 2B](#fig2){ref-type="fig"}). We also performed subgroup analyses according to breast cancer subtype. CD151 overexpression did not markedly influence OS in the Luminal B or HER2 subtypes ([Figure 3](#fig3){ref-type="fig"}). Luminal A subtype with CD151 overexpression showed a significantly poor OS (CD151-high *vs* CD151-low, 109.4 months (95% CI, 97.5--121.4) *vs* 139.6 months (95% CI, 136.2--143.0); *P*=0.0105) ([Figure 3](#fig3){ref-type="fig"}). The TNBC subtype with CD151 overexpression had a more rapid deteriorating clinical course (median OS, 91.6 months (95% CI, 76.8--106.5)) compared with that of CD151-low patients with TNBCs (median OS, 126.9 months (95% CI, 120.9--133.0)), in terms of OS (*P*=0.010) ([Figure 3](#fig3){ref-type="fig"}).

Next, the prognostic value of CD151 expression was evaluated in the subgroup analyses according to five subtypes as the QNBC subtype was expected to be insensitive to chemotherapy. CD151 overexpression did not significantly affect OS in BLBCs with CD151 overexpression, but a trend toward poorer OS did exist (CD151-high *vs* CD151-low, 99.7 months (95% CI, 81.5--117.8) *vs* 127.7 months (95% CI, 120.2--135.2); *P*=0.615). In regard to the QNBC subtype, CD151 overexpression retained its significant adverse impact on OS (CD151-high *vs* CD151-low, 74.9 months (95% CI, 54.0--95.7) *vs* 123.7 months (95% CI, 113.6--133.8); *P*=0.0170) ([Figure 3](#fig3){ref-type="fig"}).

Prognostic factor analyses
--------------------------

The factors that predicted poor OS based on the univariate analysis were CD151 overexpression, AJCC stage, cancer subtype, and adjuvant chemotherapy ([Table 2](#tbl2){ref-type="table"}). CD151 overexpression, AJCC stage, and subtype were significant prognostic factors for DFS. In the Cox regression model, the prognostic factors for OS in all of the patients were AJCC stage, breast cancer subtype, adjuvant chemotherapy, and CD151 overexpression. In regard to the DFS, only the AJCC stage retained its statistical significance at the multivariate level ([Table 3](#tbl3){ref-type="table"}). Breast cancer patients with CD151 overexpression demonstrated a substantially lower OS with a 1.65-fold (*P*=0.034; HR, 1.65; 95% CI, 1.03--2.59) higher risk of death after adjusting for AJCC stage, breast subtype, and adjuvant chemotherapy ([Table 3](#tbl3){ref-type="table"}).

Discussion
==========

The detailed clinical significance of CD151 overexpression in a large cohort of patients with breast cancer has not been previously reported. In this study of 886 breast cancer cases, we found that CD151 overexpression is an independent negative predictor of OS in patients with breast cancer and its worse impact on OS was retained in Luminal A and QBNC subtypes.

The normal expression of CD151 in the breast tissue was limited to the basal-myoepithelial cell layer surrounding both ducts and lobular alveolae, which agrees with the findings of a previous report ([@bib27]). By contrast, variable patterns of CD151 expression were seen in the invasive breast cancer tissues, which ranged from absence to diffuse, strong overexpression occurred mainly in the membrane and/or cytoplasm of the tumour cells. [@bib27] have detected the significant associations between CD151 expression and tumour grade, ER status, and combination of ER/HER2 status in 124 breast cancer cases. This is consistent with our findings because the ER-negative breast cancers, which had a higher proportion of CD151 overexpression, contained both HER2 and TNBC subtypes. Our data also indicated that the HER2 subtype had elevated CD151 expression, and that the Luminal A subtype had the lowest proportion of CD151 expression. However, they did not examine the long-term outcome or recurrence in their study, and they had calculated the CD151 positivity as 31% ([@bib27]), whereas we calculated it as 14.3% in our study. These differences in the cutoff values to identify positive cases may be controversial. However, the clinicopathological characteristics of CD151 overexpression cases were similar in both cohorts.

On the other hand, it was found in a previous study by [@bib17] that CD151 overexpression in breast cancers is associated with decreased OS based on 56 cases of breast invasive ductal carcinomas, 30.4% of which were classified as being CD151 positive. Furthermore, they have shown that CD151 expression is also positively associated with the involvement of regional lymph nodes. However, there were no associations between CD151 expression and ER status, tumour grade, disease stage, and age. Compared with these two previous studies of CD151 in breast cancer, our study utilised a larger number of cases that had sufficient follow-up data, including subtype analysis and thus this might be a reason for the discrepancy in results between this study and previous studies.

The upregulation of CD151 expression has been seen in many types of tumours and is generally associated with a poor prognosis ([@bib16]). The positive rate or proportion of CD151 overexpression that is detectable by immunohistochemistry in other cancers is variable ([Table 4](#tbl4){ref-type="table"}). Furthermore, there is no consensus for the cutoff criteria of CD151 expression. We used the scoring method of HER2 in a semi-quantitative manner and cases with a score of 3+ were considered to have CD151-high expression. CD151 overexpression occurred mainly in the membrane and/or cytoplasm in the tumour cells of the cases. As CD151 is a transmembrane protein, its functional localisation is believed to be the cellular membrane. Therefore, we did not include cases that showed only cytoplasmic expression, which was rare in our CD151-high expression group.

In agreement with poor prognosis of CD151 overexpression in several cancer types, CD151 is a metastasis-promoting tetraspanin protein. Actually, CD151-transfected cancer cell lines enhanced cell migration and invasion ([@bib12]; [@bib1]; [@bib10]). The involvement of CD151 through regulation of cell motility in metastasis was also demonstrated *in vivo* ([@bib31]). Additionally, anti-CD151 antibody treatment of high-CD151-expressing tumour cells decreased cell migration and metastasis ([@bib22]). CD151-blocking antibody was reported to inhibit invasion and intravasation at the site of the primary tumour ([@bib31]). Moreover, a recent *in vivo* study showed that CD151-null mice have markedly diminished experimental lung metastasis ([@bib18]).

In our study, CD151 overexpression was also associated with poor prognosis of breast cancer patients in line with its clinical significance in other types of cancer. In particular, high-CD151 expression was significantly correlated with a larger tumour size, higher lymph node involvement, and advanced stage of invasive breast cancer. Its association with a larger tumour size in this study can be explained by the previous findings showing that CD151 has a positive role in breast tumour cell growth *in vivo*, whereas its downregulation causes an inhibition of tumour cell growth ([@bib17]). In addition, CD151 ablation was found to inhibit the migration, invasion, and spreading of breast cancer cells in relation with its effect on the subcellular distribution of integrins, suggesting the promoting role of CD151 in breast tumour progression ([@bib27]). Furthermore, a recent study has shown that the depletion of CD151 attenuates pulmonary metastasis of breast cancer cells by regulating transforming growth factor *β* signalling ([@bib18]). These results may support the relevance of high-CD151 expression to a higher lymph node involvement and thereby advanced stage of invasive breast cancer in this study. Combination of these promoting effects of CD151 expression on breast cancer progression including tumour size and lymph node involvement may be responsible for a poor prognosis of breast cancer patients with high-CD151 expression.

However, CD151 overexpression was found to be an independent negative prognosis factor for OS but not for DFS of patients with breast cancer in this study. In regard to DFS, only the AJCC stage retained its statistical significance after adjustments for other prognostic factors including CD151 expression, subtypes, and adjuvant chemotherapy, suggesting that AJCC stage is a strong predictor of recurrence of breast cancer superior to other prognostic factors in this study. It is unclear why this difference in the effect of CD151 expression on the prediction of OS or DFS was observed. However, it is likely that CD151 expression influences the recurrence of breast cancer indirectly together with other variables, not in a direct manner, and thereby its effects on the prediction of DFS may not be as strong as AJCC stage even though high-CD151 expression was significantly correlated with recurrence of breast cancer patients in univariate analysis.

In this study, CD151 overexpression was found in 21.9% of the HER2-positive cases, which includes both HER2 and Luminal B subtypes, and was found in 27.4% of the HER2 subtype. Recently, it has been reported that CD151 is one of the mechanisms of resistance to anti-ErbB2 (HER2) agents, which suggests that targeting CD151 offers potential advantages such as drug sensitisation ([@bib26]). Interestingly, although CD151 overexpression was observed most frequently in HER2 subtype, a significant effect on survival was not shown. However, we cannot make any definitive conclusions based on this result as our cohort did not receive anti-ErbB2 (HER2) therapy. The clinical significance of CD151 overexpression in the HER2 subtype should be investigated in a cohort that has received anti-ErbB2 (HER2) therapy. CD151-*α*~6~*β*~4~ integrin complexes may influence the sensitivity to ErbB2 (HER2)-targeted therapies as *α*~6~*β*~4~ enhances the signalling of ERBB family members ([@bib5]). Constitutively activated proteins in these pathways may contribute to the clinical characteristics of HER2-positive tumours. Whether the CD151-associated HER2-positive breast cancer represents an independent disease entity remains unanswered and needs to be clarified in future studies. Thus, correlative analyses with CD151 and key proteins of these cascade pathways may be interesting to investigate so that the pathogenic role of CD151 in HER2-positive breast cancer is further clarified. CD151-high cases were rarest in the Luminal A subtype, but high-CD151 expression in this group was significantly associated with shorter OS. We also found that 16.2% of TNBC overexpressed CD151 and CD151-high cases showed a significantly poor OS consistent with the previous study demonstrating a role for CD151-*α*6 integrin complexes in basal-like breast cancer progression ([@bib27]).

In conclusion, patients with CD151 expression have a more rapid deteriorating clinical course with poorer OS compared with those not expressing the protein. CD151 expression may be a potential molecular therapeutic target for breast cancer, especially in the Luminal A and QNBC subtypes, and advanced stages of cancers. Thus, more effective treatment should be adopted in this particular subset of patients by possibly administering CD151-targeted therapy during conventional chemotherapy and HER2-targeted therapy regimens.
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###### Characteristics of patients with invasive breast cancer according to CD151 expression

                                                    **CD151 expression**                       
  ---------------------------- ------------- ------ ---------------------- ------ ----- ------ -------
  *Age at diagnosis (years)*                                                                   
   ⩽ 35                        33            3.7    30                     90.9   3     9.1    0.61
   \>35                        853           96.3   729                    85.5   124   14.5    
                                                                                                
  *Tumour size*                **\<0.001**                                                     
   T1                          363           41.0   330                    90.9   33    9.1     
   T2                          462           52.1   384                    83.1   78    16.9    
   T3                          61            6.9    45                     73.8   16    26.2    
                                                                                                
  *Lymph node involvement*     **\<0.001**                                                     
   N0                          469           52.9   420                    89.6   49    10.4    
   N1                          228           25.7   195                    85.5   33    14.5    
   N2                          109           12.3   79                     72.5   30    27.5    
   N3                          80            9.0    65                     81.3   15    18.8    
                                                                                                
  *AJCC stage*                 **\<0.001**                                                     
   I                           237           26.7   222                    93.7   15    6.33    
   II                          444           50.1   379                    85.4   65    14.6    
   III                         205           23.1   158                    77.1   47    22.9    
                                                                                                
  *Oestrogen receptor*         **\<0.001**                                                     
   Negative                    342           38.6   272                    79.5   70    20.5    
   Positive                    544           61.4   487                    89.5   57    10.5    
                                                                                                
  *Progesterone receptor*      **0.009**                                                       
   Negative                    485           54.7   402                    82.9   83    17.1    
   Positive                    401           45.3   357                    89.0   44    11.0    
                                                                                                
  *HER2*                       **\<0.001**                                                     
   Negative                    667           75.3   588                    88.2   79    11.8    
   Positive                    219           24.7   171                    78.1   48    21.9    
                                                                                                
  *Pathological type*          0.275                                                           
   Ductal                      812           91.6   691                    85.1   121   14.9    
   Lobular                     25            2.8    22                     88.0   3     12.0    
   Others                      49            5.5    46                     93.9   3     6.12    
                                                                                                
  *Breast cancer subtype*      **\<0.001**                                                     
   Luminal A                   451           50.9   407                    90.2   44    9.8     
   Luminal B                   113           12.8   94                     83.1   19    16.8    
   HER2                        106           12.0   77                     72.6   29    27.4    
   TNBC                        216           24.4   181                    83.8   35    16.2    
    BLBC                       135           15.2   113                    83.8   22    16.2    
    QNBC                       81            9.1    68                     84.0   13    16.0    
                                                                                                
  *CK5/6*                      0.274                                                           
   Negative                    760           85.8   655                    86.2   105   13.8    
   Positive                    126           14.2   104                    82.5   22    17.5    
                                                                                                
  *EGFR*                                                                                       0.336
   Negative                    762           86.0   649                    85.2   113   14.8    
   Positive                    124           14.0   110                    88.7   14    11.3    
                                                                                                
  *Adjuvant Chemotherapy*      0.409                                                           
   No                          148           16.7   130                    87.8   18    12.2    
   Chemotherapy                738           83.3   629                    85.2   109   14.8    

Abbreviations: AJCC=American Joint Committee on Cancer; BLBC=basal-like breast cancer; HER2=human epidermal growth factor receptor 2; QNBC=quintuple-negative breast cancer; TNBC=triple-negative breast cancer. Statistically significant *P*-values (*P*\<0.05) are shown in bold.

###### Univariate analysis of the overall survival and progression-free survival in 886 patients with invasive breast cancer

                             **Overall survival**  **Disease-free survival**                        
  ------------------------- ---------------------- --------------------------- -------------------- -------------
  *CD151 expression*                                                                                
   Low                              90/759                                           177/759         
   High                             35/127         **\<0.001**                        41/127        **0.021**
                              2.50 (1.688-3.687)                                1.50 (1.064-2.099)   
                                                                                                     
  *AJCC stage*                                                                                      
   I                                10/237                                            31/237         
   II                               54/444         **0.001**                          93/444        **0.013**
                              3.00 (1.526-5.883)                                1.67 (1.114-2.512)   
   III                              61/205         **\<0.001**                        94/205        **\<0.001**
                              8.09 (4.416-15.79)                                4.32 (2.879-6.489)   
                                                                                                     
  *Subtype*                                                                                         
   Luminal A                        38/451                                           102/451         
   Luminal B                        18/113         **0.017**                          36/113        **0.020**
                              1.98 (1.131-3.471)                                1.57 (1.073-2.294)   
   HER2                             28/106         **\<0.001**                        33/106        **0.027**
                              3.30 (2.020-5.376)                                1.56 (1.053-2.309)   
   TNBC                             41/216         **\<0.001**                        47/216        0.858
                              2.39 (1.533-3.712)                                1.03 (0.730-1.458)   
                                                                                                     
  *Adjuvant chemotherapy*                                                                           
   No                               33/148                                            30/148         
   Yes                              92/738         **0.009**                         188/738        0.223
                              0.59 (0.394-0.874)                                1.27 (0.864-1.868)   

Abbreviations: AJCC=American Joint Committee on Cancer; CI=confidence interval; HER2=human epidermal growth factor receptor 2; TNBC=triple-negative breast cancer. Statistically significant *P*-values (*P*\<0.05) are shown in bold.

###### Multivariate analysis of the overall survival and progression-free survival in 886 patients with invasive breast cancer

                            **Overall survival**   **Disease-free survival**                        
  ------------------------- ---------------------- --------------------------- -------------------- -------------
  *CD151 expression*                                                                                
   Low                                                                                               
   High                     1.65 (1.03-2.59)       **0.034**                   1.15 (0.814-1.634)   0.421
                                                                                                     
  *AJCC stage*                                                                                      
   I                                                                                                 
   II                       3.57 (1.791-7.103)     **\<0.001**                 1.63 (1.072-2.473)   **0.022**
   III                      11.5 (5.724-23.17)     **\<0.001**                 4.25 (2.766-6.531)   **\<0.001**
                                                                                                     
  *Subtype*                                                                                         
   Luminal A                                                                                         
   Luminal B                1.63 (0.926-2.868)     0.090                       1.44 (0.980-2.109)   0.063
   HER2                     2.49 (1.518-4.091)     **\<0.001**                 1.40 (0.941-2.092)   0.097
   TNBC                     3.08 (1.969-4.815)     **\<0.001**                 1.18 (0.831-1.675)   0.356
                                                                                                     
  *Adjuvant chemotherapy*                                                                           
   No                                                                                                
   Yes                      0.30 (0.195-0.451)     **\<0.001**                 0.88 (0.584-1.309)   0.514

Abbreviations: AJCC=American Joint Committee on Cancer; CI=confidence interval; HER2=human epidermal growth factor receptor 2; TNBC=triple-negative breast cancer. Statistically significant *P*-values (*P*\<0.05) are shown in bold.

###### CD151 expressions and positive rates in variable epithelial malignancy as measured by the immunohistochemical method

                    **Country**   **Year**   **Organ**  **Cancer type**                   **Number**   **Tissue**        **Antibody**             **Titer**    **Incubation**  **% positive**   **Cutoff of positive cases**                                                       **Survival data**   **Multivariate data**
  ---------------- ------------- ---------- ----------- --------------------------------- ------------ ----------------- ---------------------- ------------- ---------------- ---------------- --------------------------------------------------------------------------------- ------------------- -----------------------
  1\. This study       Korea        2011      Breast    Invasive carcinoma                886          FFPE, TMA         RLM30, Novocastra         1 : 100        2 h, RT      14.6             3+ with diffuse complete membrane stating                                                 Yes                   Yes
  2\. [@bib27])         USA         2008      Breast    Invasive ductal carcinoma         124          FFPE, TMA         RLM30, Novocastra         1 : 50            NA        31.0             2+ or 3+                                                                                 None                  None
  3\. [@bib17])         UK          2009      Breast    Invasive ductal carcinoma         56           FFPE              RLM30, Novocastra         1 : 50            NA        30.4             \>10% of positive cells with weak to strong complete membrane staining                    Yes                  None
  4\. [@bib24])         UK          2011      Uterus    Endometrial cancer                131          FFPE, TMA         RLM30, Novocastra         1 : 50            NA        58.7             \>H-score 150                                                                             Yes                   Yes
  5\. [@bib28]         Korea        2011      Kidney    Clear cell carcinoma              489          FFPE, TMA         RLM30, Novocastra         1 : 100        1 h, RT      47.5             \>50% of positive cells with diffuse moderate or strong intensity                         Yes                   Yes
  6\. [@bib21])        Japan        2010     Esophagus  Squamous cell carcinoma           138          FFPE              RLM30, Novocastra         1 : 50      4°C overnight   54.3             \>10% of positive cells with weak to strong complete membrane staining                    Yes                   No
  7\. [@bib9]          China        2010       Liver    Intrahepatic cholangiocarcinoma   140          FFPE, TMA         11G5a, Serotec            1 : 200           NA        53.6             \>50% of tumour cells                                                                     Yes                   Yes
  8\. [@bib11])        China        2009       Liver    Hepatocellular carcinoma          520          FFPE, TMA         11G5a, Serotec            1 : 100           NA        59.8             \>50% of tumour cells                                                                     Yes                   Yes
  9\. [@bib30])        China        2011     Pancreas   Ductal adenocarcinoma             71           FFPE              sc-80715, Santa Cruz      1 : 00         1 h, RT      81.7             4--7 points, moderate to strong intensity                                                 Yes                   Yes
  10\. [@bib2])      Australia      2004     Prostate   Adenocarcinoma                    76           FFPE              11B1, purified IgG2a    4 ug ml^−1^      2 h, RT      23.0             \>17.52 density and area measured by digitised image[a](#t4-fn3){ref-type="fn"}           Yes                  None
  11\. [@bib6])        Japan        2003       Colon    Adenocarcinoma                    146          Frozen sections   SFA1.2B4                    NA           2 h, RT      55.5             \>120 multiplying of intensity and percentage of cells                                    Yes                   Yes
  12\. [@bib23])       Japan        2001       Lung     Non-small cell carcinoma          145          Frozen sections   SFA1.2B4                    NA           2 h, RT      54.5             \>50% of tumour cells                                                                     Yes                   Yes

Abbreviations: FFPE=formalin fixed paraffin embedded; NA=not available; RT=room temperature; TMA=tissue microarray.

Yes: The study contains negative correlation data between survival and CD151 overexpression; No: CD151 overexpression is not an independent factor for poor survival; None: the study does not contain survival data.

Only cytoplasmic regions of the epithelial cell were measured.

[^1]: These authors contributed equally to this work.
